bromodomain


Also found in: Wikipedia.

bromodomain

A 110-amino acid protein domain which recognises acetylated lysine residues on the N-terminal tails of histone. It is present in over 100 proteins, especially chromatin-associated proteins—e.g., gnc5, peregrin, Snf2, tafii-250.
References in periodicals archive ?
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor.
The trial will evaluate the combination, safety and efficacy of the Company's ZEN-3694, a novel and differentiated bromodomain and extra-terminal domain inhibitor, and Pfizer's talazoparib, a poly ADP ribose polymerase inhibitor, in patients with locally advanced or metastatic triple negative breast cancer without germline BRCA1/2 mutations.
According to Nuevolution, it has developed potent and selective compounds, with a benign safety profile, targeting the first bromodomain of the BET family of proteins.
Histone acetylated lysines, under the control of the opposite action of HATs and HDACs, are recognized by bromodomain and extra-terminal (BET) proteins.
has signed an exclusive global license agreement that provides OHM Oncology with the rights for the development, manufacture and commercialization of APL-581, as well as related molecules from Aptose's dual bromodomain and extra-terminal domain motif (BET) protein and kinase inhibitor program.
Microarray experiments conducted on leukemia cell lines treated with the bromodomain inhibitor JQ1 showed that JQ1 causes a significant downregulation of S100A8 and S100A9 transcripts in OCI-AML3 cells (Figure 1).
Held et al., "SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells," Oncotarget, vol.
demonstrated that the inhibition of bromodomain protein BRD4 could alleviate the expression of oncogenic lncRNA HOTAIR in GBM patients, exerting an antiproliferation effect by inducing cell cycle arrest in GBM cells [160, 161].
DNMT inhibitors (DNMTi), histone deacetylase inhibitors (HDACi), and inhibitors of the bromodomain and extraterminal motif proteins (iBET), approved by the US Food and Drug Administration (FDA), are actually in clinical trials for several malignancies and they are reviewed in detail in [160].
The family of bromodomain and extraterminal (BET) proteins is composed of four members: BRD2, BRD3, BRD4 (ubiquitously expressed), and BRDT.